PHASE II TRIAL OF SEQUENTIAL MODIFICATION OF IMMUNOSUPPRESSION, INTERFERON ALPHA, AND PROMACE-CYTABOM FOR TREATMENT OF POST-CARDIAC TRANSPLANT LYMPHOPROLIFERATION.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Immunosuppressants; Interferon alpha; Methotrexate; Prednisone; Vincristine
- Indications Post-transplant lymphoproliferative disorder
- Focus Therapeutic Use
- 24 Jan 2013 Biomarkers information updated
- 12 Jan 2012 Actual patient number is 20 according to ClinicalTrials.gov.
- 12 Jan 2012 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.